Article
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Cancer research - 15 Oct 2015
Soucheray Margaret, Capelletti Marzia, Pulido Inés, Kuang Yanan, Paweletz Cloud P, Becker Jeffrey H, Kikuchi Eiki, Xu Chunxiao, Patel Tarun B, Al-Shahrour Fatima, Carretero Julián, Wong Kwok-Kin, Jänne Pasi A, Shapiro Geoffrey I, Shimamura Takeshi
Abstract excerpt
Non-small cell lung cancers (NSCLC) that have developed resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), including gefitinib and erlotinib, are clinically linked to an epithelial-to-mesenchymal transition (EMT) phenotype. Here, we examined whether modulating EMT maintains the responsiveness of EGFR-mutated NSCLCs to EGFR TKI therapy. Using human NSCLC cell lines harboring mutated EGFR and a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.